In the dynamic world of research-oriented psychedelic substances, LSD analogues have taken on a notable prominence in recent years, becoming a focus of attention for laboratories and for communities interested in the chemistry of altered states of consciousness. This is no coincidence: it reflects a combination of scientific, regulatory and cultural factors that have driven the development of new molecules capable of expanding knowledge in pharmacology, neuroscience and structure–activity relationships.
Within this landscape, compounds such as 1S-LSD, 1V-LSD, 1cP-LSD and 1D-LSD represent the cutting edge of this innovation, offering chemically distinct profiles for study. Although all are structurally related to classic LSD, each incorporates specific modifications — mainly in the substituent group on the indole nitrogen — that alter its chemical identity, its stability and, potentially, its behaviour in research settings. These variations are not mere “cosmetic changes” but deliberate adjustments that make it possible to study in greater detail how small molecular differences can influence parameters such as receptor affinity, metabolism, bioavailability and duration of effects in experimental models.
From a scientific standpoint, these analogues offer a valuable opportunity to explore structure–activity relationships (SAR), to look more closely at mechanisms of action linked to serotonergic receptors — especially 5-HT2A — and to better understand the interaction between psychedelics and neural networks. In some cases, the possibility that they act as prodrugs (compounds that are converted into LSD or other active molecules through metabolic processes) is also being investigated, which opens an additional field of study on metabolic kinetics and in vivo conversion.
Alongside academic interest there is also a key regulatory component. The appearance of these substances is often tied to the legal margins of certain countries, where small structural modifications can temporarily place a compound outside explicit control lists. However, this is a changeable and complex matter: the legality of each analogue depends on the jurisdiction, on rules about “analogues” or “similar substances”, and on frequent updates to national legislation. Any responsible discussion must therefore stress that the legal situation can change quickly and that legal analysis must always be rigorous, up to date and contextualised.
What are 1x-series LSD analogues?
1x-series LSD analogues, often called “prodrugs” or “research chemicals” (RCs), are a family of compounds belonging to the lysergamides, that is, molecules closely related to classic LSD-25. Chemically, they are derivatives designed through specific structural modifications — for example, adding groups such as propionyl, butyryl, valeryl, cyclopropionyl, among others — at particular positions of the molecule (usually the indole nitrogen, giving rise to 1x-LSD type analogues). These small alterations make it possible to create new substances that, although they keep the characteristic lysergic “core”, have a distinct chemical identity.
The logic behind this design is twofold. On the one hand, the aim is to explore how certain changes affect properties relevant to study, such as chemical stability, solubility, receptor affinity, duration of action or metabolic profile. On the other, there is a widely discussed premise: that many of these analogues act as prodrugs, that is, compounds that are not necessarily the final active agent but are transformed inside the body into another substance — here, potentially LSD-25 — through metabolic processes such as enzymatic hydrolysis or removal of the added group.
Put simply: some of these derivatives may work as a kind of “chemical vehicle” that, once ingested, releases LSD wholly or partly in the body, which would explain why their reported effects are sometimes very similar to those of traditional LSD. However, the degree of conversion, the metabolic rate and the by-products generated can vary significantly depending on the compound, the organism and the context, which makes these analogues a particularly interesting field for pharmacological and toxicological research.
Legal and chemical evolution of LSD analogues:
| Analogue | Typical research dose | Key notes and legal context |
|---|---|---|
| 1P-LSD | 100–150 mcg | One of the first widely distributed analogues. It is regarded as the prototype of the “1-acylated” lysergamides and is often described as a prodrug of LSD-25. Its popularity made it an early target for regulation. |
| 1cP-LSD | 100–150 mcg | A later evolution of 1P-LSD with a different substituent (cyclopropionyl). It gained notoriety through reports of a “clean” or stable profile, although these descriptions are mostly anecdotal. It appeared in response to regulatory pressure on earlier analogues. |
| 1V-LSD (Valeryl) | 150–225 mcg | A more recent derivative (valeryl), associated with a new wave after restrictions on earlier compounds. It is frequently sold both in “standard” formats and in low-quantity forms for microdosing protocols. |
| 1D-LSD / 1T-LSD | 225 mcg | A relatively recent N1-acylated lysergic analogue, developed after 1P-/1cP-/1V-LSD. It is characterised by carrying an N1 substituent different from the “classic” acyl groups (propionyl, cyclopropionyl or valeryl). Its name can vary (including the label 1T-LSD) depending on the supplier or the local framework, which adds complexity to traceability and to comparing sources. |
| 1S-LSD | 150 mcg | A current analogue of interest, available in standard doses and for microdosing protocols. |
What are LAD-series LSD analogues?
Compounds of the LAD series (for example AL-LAD, ETH-LAD and PRO-LAD) also belong to the lysergamide family, but differ from 1X-LSD analogues in one fundamental respect: they are not based on acylation of the indole nitrogen (N1), but on direct modifications to the amide region of the molecule, a critical zone for pharmacological interaction.
In other words, while many 1X-LSDs are described as possible prodrugs (derivatives designed to be metabolically converted to LSD-25), LAD analogues are better understood as direct structural analogues with a profile of their own. Changing the substituent on the amide alters the chemical identity more substantially and, potentially, the receptor affinity, relative potency and overall character of the compound.
The logic behind developing the LAD series is more tied to the scientific exploration of structure–activity relationships (SAR) than to simple legal substitution. These compounds make it possible to study how relatively small changes in the amide region can alter key parameters of lysergic pharmacology, offering a valuable basis for comparison with LSD-25 and with 1X analogues.
Although they have circulated in “research chemistry” circles for years, it is important to remember that solid clinical evidence on these derivatives is limited, and their legal status is usually restrictive or ambiguous depending on the country, especially under rules that control structural analogues.
Legal and chemical evolution of LAD analogues:
| Analogue | Typical research dose | Key notes and legal context |
|---|---|---|
| AL-LAD | 75–150 mcg | One of the best-known LAD derivatives. It modifies the amide region (N6), so it is considered a direct analogue with its own identity. In many jurisdictions it may be explicitly controlled or covered by analogue laws. |
| ETH-LAD | 75–150 mcg | A variant closely related to AL-LAD, with a different substitution on the amide. Of interest for SAR studies because of its structural closeness to LSD-25. Its legal status is usually especially sensitive because of that similarity. |
| PRO-LAD | 100–200 mcg | A less widespread derivative that extends the SAR map of the series. It allows the impact of a bulkier substituent in the amide region to be assessed. Legality varies by jurisdiction. |
What are other lysergic derivatives such as LSZ, MiPLA, EiPLA or LSP?
Besides 1X-LSD analogues and the LAD series, there is a group of compounds that often appear in guides and catalogues under the general label of “LSD analogues” but are really a more diverse category: structurally distinct lysergic derivatives or ergolines.
These include molecules such as LSZ, MiPLA, EiPLA or LSP, which do not necessarily follow the “acyl at N1” pattern or fit the classic LAD series. In some cases they represent chemical explorations aimed at modifying other parts of the molecule to observe changes in pharmacology, duration or receptor selectivity. In others, they are attempts to widen the catalogue of lysergamides without resorting to the same repeated substitution strategy.
The importance of this group in a guide is that it shows lysergic chemistry is not limited to a single “recipe”: innovation also happens by alternative routes, even though many of these substances are less well known and have less consolidated public literature. From a legal point of view, these compounds can present even more uncertainty: some may not be listed by name but may be open to regulation under broad definitions of analogue, “derivatives”, or because of their functional similarity to LSD.
Assorted lysergic derivatives (overview):
| Compound | Typical research dose | Key notes and legal context |
|---|---|---|
| LSZ | 150 mcg | An ergoline derivative with a structure different from LSD-25. It is neither 1X nor LAD. Interesting for exploring a different chemical space within the lysergamides. |
| MiPLA | 150–300 mcg | A lysergamide with a modification in the amide region, but outside the typical LAD pattern. Less documented in the open literature; included for its SAR relevance. |
| EiPLA | 150–300 mcg | A close relative of MiPLA with a different substitution. Useful for comparison within “PLA derivatives”. Legality varies. |
| LSP | 50–150 mcg | A less common derivative. It often appears in analogue lists, but with less consensus and public documentation. |
What are natural lysergamides (LSA and related)?
Finally, many “LSD analogue guides” include references to compounds such as LSA (ergine) and other natural lysergamides found in the seeds of certain plants. Although they are not synthetic analogues in the modern sense, they belong to the same broad chemical universe: lysergic acid derivatives.
These substances matter for historical and chemical reasons: they show that the ergoline core occurs naturally and that interest in lysergamides predates the development of LSD-25. However, their pharmacological profile usually differs from that of LSD, with reported effects that are more sedating or more physically heavy, and their legal status varies widely by country.
Natural and related lysergamides:
| Compound | Typical research dose | Key notes and legal context |
|---|---|---|
| LSA (ergine) | 500–1500 mcg | The main natural lysergamide in seeds. It shares a chemical family with LSD, but its profile is different. Legality varies by jurisdiction. |
| Ergometrine (ergonovine) | variable | An alkaloid associated with medical uses in certain contexts. Historically relevant for understanding the chemistry of ergot and lysergic derivatives. Heavily regulated. |
| LSH (mentioned/controversial) | variable | Sometimes cited as a related natural derivative. Its real presence and stability in preparations is debated. It is mentioned more for historical interest than for chemical standardisation. |
Ethical and safety considerations in research
The study of any psychoactive substance, especially research analogues, carries fundamental ethical and safety responsibilities:
- Legal status. The status of these compounds varies enormously by country and can change quickly. What is legal for research in one place may be a controlled substance in another. Legal due diligence is the mandatory first step for any researcher.
- Purity and dosage. Obtaining substances from suppliers who provide purity analysis (HPLC, GC-MS) is essential to ensure that what is being studied is the stated compound, at the specified dose and free of dangerous adulterants.
- Research context (set and setting). This fundamental principle of psychedelic safety applies even in preclinical research or documented self-experimentation. A safe, controlled environment and a prepared mindset are non-negotiable elements for minimising risk.
- Transparency and non-promotion. Information on these substances must be presented objectively and scientifically, without any intent to promote their use. Language must be precise, avoiding recreational terminology and stressing their nature as chemical research tools.
The LSD analogue market reflects a complex phenomenon at the intersection of chemical innovation, drug policy and scientific interest in modifying consciousness. For the research community, the priority must always be methodological rigour, safety and strict adherence to the legal framework in force. The future of this field will depend on the ability to generate valuable and ethical knowledge from the study of these fascinating molecules.
This article is strictly informational and educational in nature, about chemical and research trends. It does not constitute legal or medical advice or a recommendation to use any substance. Many of these compounds may be illegal in your country or jurisdiction. The use of psychoactive substances can carry significant risks to physical and mental health. Always check local laws and seek the advice of health and research professionals before engaging in any related study.



